Nanomedicine review: clinical developments in liposomal applications

• Main Authors: Esteban Beltrán-Gracia, Adolfo López-Camacho, Inocencio Higuera-Ciapara, Jesús B Velázquez-Fernández, Alba A Vallejo-Cardona
• Format: Article
• Language: English
• Published: BMC 2019-12-01
• Series: Cancer Nanotechnology
• Subjects: Drug delivery systems; Nanoscale; Liposomal nanotechnology; Recent clinical trials
• Online Access: https://doi.org/10.1186/s12645-019-0055-y
• ISSN: 1868-6958; 1868-6966

Abstract Background In recent years, disease treatment has evolved strategies that require increase in pharmaceutical agent’s efficacy and selectivity while decreasing their toxicity in normal tissues. These requirements have led to the development of nanoscale liposome systems for drug release. This review focuses on lipid features, pharmacological properties of liposomal formulations and the clinical studies of their application. Main body Several lipids are available, but their properties could affect pharmacological or clinical efficiency of drug formulations. Many liposomal formulations have been developed and are currently on the market. Proper selection of lipid is essential for the pharmacological effect to be improved. Most of the formulations use mainly zwitterionic, cationic or anionic lipids, PEG and/or cholesterol, which have different effects on stability, pharmacokinetics and delivery of the drug formulation. Clinical trials have shown that liposomes are pharmacologically and pharmacokinetically more efficient than drug-alone formulations in treating acute myeloid leukemia, hepatitis A, pain management, ovary, gastric breast and lung cancer, among others. Conclusion Liposomal formulations are less toxic than drugs alone and have better pharmacological parameters. Although they seem to be the first choice for drug delivery systems for various diseases, further research about dosage regimen regarding dose and time needs to be carried out.